Biotechnology advances · 2026
Designing gene expression with MPRA and AI: A new paradigm for synthetic and therapeutic regulation.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Xue, Huang Xiao-Yan, Wang Hui-Yu, Bai Feng-Wu, Li Kai, Hu Shen S
Аннотация
Precise and scalable control of gene expression across biological contexts remains a fundamental challenge in synthetic biology and therapeutic development, and massively parallel reporter assays (MPRAs) have emerged as a transformative platform for systematically interrogating cis-regulatory elements (CREs) and enabling high-throughput and quantitative dissection of sequence-dependent transcriptional activity to address this challenge. Beyond their original role in empirical characterization, the convergence of barcoded MPRA technologies with deep learning-based modeling has substantially expanded their impact, facilitating predictive inference and the de novo design of synthetic regulatory elements with programmable behavior. In this review, we synthesize recent advances in barcoded MPRA platforms and AI-driven modeling frameworks for the rational engineering of CREs with tunable transcriptional strength and specificity. We further highlight cutting-edge applications in microbial synthetic biology, mRNA therapeutics, and cell-specific gene regulation, emphasizing the role of barcoded MPRA in supporting data-efficient and cross-context generalizable design. Finally, we discuss current technical and conceptual limitations and future directions toward safe, programmable, and clinically relevant regulatory control systems, outlining a roadmap for next-generation cis-regulatory engineering and gene therapies.